American BioMed Inc. reports improvement in year-end earnings.

THE WOODLANDS, Texas--(BUSINESS WIRE)--April 3, 1996--American BioMed Inc. (OTC BB:ABMI), of The Woodlands, Wednesday announced 1995 year-end financial results showing a loss of $(.15) per share vs. a loss of $(.46) per share, for 1994.

The year-end results were favorably impacted by technology sales and option fees, reduced operating expenses and a 23.4% increase in Cathlab product sales year to year. The technology sales result from the company's implementation of its strategic plan to "unbundle" its various technologies and the rights appurtenant to such technologies in specific geographic areas. Cathlab product sales increased as a result of implementing the company's business plan to revamp its distributor network by replacing underperforming distributors.

Overall sales increased 3.7% and Cathlab's improved sales performance was partially offset by the company's decision to discontinue certain product lines which were not in keeping with the company's strategic focus. Revenues of discontinued products were $154,294 in 1994 and were partially offset by increased sales of the company's core products in 1995.

American BioMed President, Steven Rash also announced that "the company's 510(k) document for final FDA submission for its peripheral OmniCath(r) will be filed by May 1, 1996." He elaborated further stating "the company intends to compile its FDA submission for the OmniStent(tm) this year and initiate clinical trials for its Endovascular product line. The company will focus its efforts during the last nine months of 1996 on Cathlab product sales and the continuing efforts to reduce operating costs through the successful implementation of its revised business plan."

American BioMed Inc., is engaged in the development, manufacture and marketing of next generation minimally invasive medical, surgical and diagnostic devices which deliver unique advantages through advanced technology. OmniStent(tm), which incorporates the company's (U.S. and European) patented "endless loop" process, offers the physician a choice in configurations and more options (including bifurcations) than any other stent in this $1-billion market. Other devices are spinal dissectors and unique silicon catheters. OmniCath(r) is a directional atherectomy catheter that employs deflecting nontraumatizing wires to anchor the cutting window at the atherectomy site. Directional atherectomy is an alternative and adjunct to angioplasty and stent procedures intended to treat peripheral vascular disease. -0-

                           American BioMed Inc.
                              April 1, 1996

                   Consolidated Statements of Operations

                                    Year          Year
                                   Ended         Ended
                                  Dec. 31,      Dec. 31,
                                    1994          1995
                                  --------      --------
Sales, net                       $ 637,375     $ 660,770
Operating costs and expenses:
 Cost of sales                    (782,729)     (649,355)
 Selling, general and
  administrative expenses       (2,235,116)   (2,169,591)
 Research and development
  expenses                      (1,167,773)     (537,962)

    Loss from operations        (3,548,243)   (2,696,138)

Other income (expense):
 Interest income                       902         7,239
 Interest expense                 (182,606)     (276,688)
 Other income (expense)            (56,209)    1,561,203

    Other income (expense), net   (237,913)    1,291,754

    Net loss                   $(3,786,156)  $(1,404,384)

Net loss per share                  $(0.46)       $(0.15)

Weighted average number
 of shares outstanding           8,188,980     9,362,198

CONTACT: Thomas E. Waite & Associates Inc., Lake Mary, Fla.

Phone [phone]/Fax [phone]